ストックスクリーナーアプリを入手
927.89
13.33%
109.12
アフターアワーズ：
926.00
-1.89
-0.20%
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Pre-Markets in Red on Massive AI Spending Concerns - Zacks Investment Research
Pre-Markets Spooked on Questions Regarding AI, Oil Prices - Zacks Investment Research
Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise - Zacks Investment Research
Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc.EYPT - GlobeNewswire Inc.
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness - GlobeNewswire Inc.
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) - GlobeNewswire Inc.
Facing Investing Fears - The Motley Fool
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research
Regeneron Pharmaceuticals, Inc. $REGN Shares Newly Bought by Cantor Fitzgerald Investment Advisors L.P. - MarketBeat
Are You Overpaying For Regeneron Stock Versus Its Rivals? - Trefis
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Bump from TD Cowen - MarketBeat
TD Cowen maintains Buy rating on Regeneron Pharmaceuticals, $980 price target - TradingView
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
EyePoint to halve workforce after experimental drug fails second late-stage trial - Reuters
Strong Dupixent Trajectory Anchors Regeneron Pharmaceuticals’ (REGN) Solid Financial Results - Yahoo Finance
How Much Upside Is Left In Regeneron Stock? - Yahoo Finance
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market - The Motley Fool
Regeneron Pharmaceuticals, Inc. (REGN) options chain - Yahoo Finance Australia
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share - The Motley Fool
Regeneron Pharmaceuticals, Inc. (REGN) options chain - Yahoo Finance UK
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types - GlobeNewswire Inc.
Regeneron Pharmaceuticals (REGN) Rallies On Earnings Beat As Undervalued Narrative Holds - Yahoo Finance
Regeneron (REGN) Stock Still Looks Below Fair Value On Fresh Trial Data - Yahoo Finance
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research
Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research
What to Expect From Regeneron Pharmaceuticals' Next Quarterly Earnings Report - Barchart.com
Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
RBC raises target for Regeneron stock to USD 810.00 - ad-hoc-news.de
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
Regeneron reports 84-week Phase III data for Pasatru in adult FOP - Yahoo Finance
Regeneron reports Pasatru data and Citi holds Regeneron stock - ad-hoc-news.de
Regeneron presents new long-term data for Pasatru - The Pharma Letter
Regeneron reports 84-week Pasatru results: stock pre-market at EUR 684.95 - ad-hoc-news.de
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron’s New Drug Halts Rogue Bone Growth EffectivelyRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga
Regeneron Reports Sustained 84-Week Efficacy Data for Pasatru in Adults With FOP - Quiver Quantitative
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Regeneron’s Rare Disease Drug Shows Zero New Abnormal Bone Growth In Extended Trial – REGN Stock Heads For Best Day In Over A Month - Stocktwits
Should Alliance Expansion Require Action From Regeneron (REGN) Investors? - Simply Wall Street
Regeneron Pharmaceuticals, Inc. (REGN) options chain - Yahoo Finance Australia
Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative - Simply Wall Street
Why Regeneron (REGN) is a Top Value Stock for the Long-Term - Zacks Investment Research
Regeneron Pharma Is Maintained at Sector Perform by RBC Capital - Moomoo
0.47%
3.50%
大文字化:
|
ボリューム (24 時間):